-
The Future Of Nano Technology
Categories
- Ai
- Alan Watts
- Anatomy
- Andropause
- Anti-Aging Medicine
- Arthritis
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ataxia
- Autism
- Biochemistry
- BioEngineering
- Biotechnology
- Bitcoin
- Chemistry
- Cryonics
- Cryptocurrency
- David Sinclair
- Dementia
- Diet Science
- Diseases
- Eczema
- Elon Musk
- Futurism
- Gene Medicine
- Gene Therapy
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Healthy Lifestyle
- Healthy Living
- HGH Physicians
- Hormone Optimization
- Hormone Replacement Therapy
- Hormone Replacement Treatment
- Human Genetic Engineering
- Human Immortality
- Human Longevity
- Human Reproduction
- Hypogonadism
- Hypopituitarism
- Hypothyroidism
- Immortality
- Immortality Medicine
- Inflammation
- Injectable Growth Hormone
- Integrative Medicine
- Life Skills
- Longevity
- Longevity Medicine
- Low T
- Machine Learning
- Mars Colony
- Medical School
- Menopause
- multiple-sclerosis
- Nano Medicine
- Nanomedicine
- Nanotechnology
- Neurology
- Parkinson's disease
- Pharmacogenomics
- Protein Folding
- Psoriasis
- Quantum Computing
- Regenerative Medicine
- Resveratrol
- Sermorelin Physicians
- Singularity
- Spacex
- Stem Cell Therapy
- Stem Cells
- Stemcell Therapy
- Testosterone
- Testosterone Physicians
- Transhuman
- Transhumanism
- Transhumanist
- Uncategorized
- Veganism
- Vegetarianism
- Vitamin Research
- Wellness
-
Recent Posts
- Nanoscope Therapeutics: Gene Therapy Improves Visual Acuity in Patients with Retinitis Pigmentosa – 2 Minute Medicine
- College of Engineering Launches New Collaboratory for Biomedical and Bioengineering Innovation – UConn Today – University of Connecticut
- "The best decision I ever made:" Patel earns degree in biological engineering – University of Missouri College of Engineering
- Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute … – Nature.com
- Pharmacogenomics could improve medication safety and reduce waste – Healthcare IT News
Archives
Popular Key Word Searches
- centraltph
- bicarbonate and growth immunity ray peat
- vrcc neurology
- bibliotecapleyades/amrita-longevity-immortality
- cbr xmen anatomy
- Medical genetics wikipedia
- immortality medicine
- GrabPay
- Grab Pay Philippines
- GrabPay Vietnam
- GrabPay Philippines
- dr weil psoriasis
- what does recovered mean covid-19
- tony pantalleresco
- tony pantalleresco herbalist book
- herbsplusbeadworks
- herbsplusbeadworks website
- hailie vanderven
- princeton longevity center scam
- aetna genetic testing policy
- anatomy of hell
- biggie
- longevity claims
- augmentinforce tony pantalleresco
- tony pantalleresco website
Search Immortality Topics: |
Category Archives: Stem Cells
Meager Coverage of Yesterday’s Bristling IOM-CIRM Meeting
Mainstream news coverage today was skimpy, to put it mildly, of the testy session yesterday involving the governing board of the California stem
cell agency and representatives of the prestigious Institute of
Medicine(IOM).
Only two pieces appeared, one in the
San Diego U-T and another on the web site of the Los Angeles Times. Both
discussed what the Michael Hiltzik of the Times column called “overt hostility” on the
part of several board members (see yesterday's item here). Bradley
Fikes of the San Diego paper said the patient advocates on the board
“strongly criticized” the IOM report on the grounds that it
“unfairly suggests that they have a conflict of interest.”
San Diego U-T and another on the web site of the Los Angeles Times. Both
discussed what the Michael Hiltzik of the Times column called “overt hostility” on the
part of several board members (see yesterday's item here). Bradley
Fikes of the San Diego paper said the patient advocates on the board
“strongly criticized” the IOM report on the grounds that it
“unfairly suggests that they have a conflict of interest.”
One of the recommendations of the IOM
is that the agency develop ways to manage personal conflicts of
interest dealing with patient advocates and others at the agency.
is that the agency develop ways to manage personal conflicts of
interest dealing with patient advocates and others at the agency.
Fikes wrote,
"'I'm a
colon cancer survivor,' said Art Torres, vice chairman of the
oversight committee, and a patient advocate designate. 'Does having
colon cancer make me biased?'
“Jeff
Sheehy, another patient advocate designate, protested what he called
a 'defenestration' of patient advocates, whose interests often span
multiple diseases.”
Ron Leuty of the San Francisco Business
Times skipped the IOM matter and wrote about the awarding of $36
million in grants. However, a list of the most popular stories on the
Business Times web site, ranked as No. 5 Leuty's story last week on the IOM
study, just below an article about Stanford's $111 million
concert hall.
Times skipped the IOM matter and wrote about the awarding of $36
million in grants. However, a list of the most popular stories on the
Business Times web site, ranked as No. 5 Leuty's story last week on the IOM
study, just below an article about Stanford's $111 million
concert hall.
Fikes also had a piece on ViaCyte,
which is in his area, receiving another $3 million from CIRM.
which is in his area, receiving another $3 million from CIRM.
Posted in Stem Cell Therapy, Stem Cells
Comments Off on Meager Coverage of Yesterday’s Bristling IOM-CIRM Meeting
LA Times: On the California Stem Cell Agency and Wasting $700,000
The headline on the Los Angeles
Times web site this afternoon read,
"Is California's stem cell program
preparing to waste $700,000?"
The question was raised by Pulitzer
Prize-winning columnist Michael Hiltzik, whowas commenting on the presentation today by the
prestigious Institute of Medicine's (IOM) on its sweeping
recommendations for changes at the state stem cell agency.
Prize-winning columnist Michael Hiltzik, whowas commenting on the presentation today by the
prestigious Institute of Medicine's (IOM) on its sweeping
recommendations for changes at the state stem cell agency.
Hiltzik wrote,
"If you're betting that
the California
stem cell agency will spurn key recommendations of a
blue-ribbon review panel that criticized its leadership and
management structures, you might want to double that bet. Several
board members showed overt hostility to the panel's recommendations
during a public meeting today."
Harold Shapiro, chairman of the IOM
panel and former president of Princeton University, delivered
the briefing. The group's study took 17 months and cost the stem cell
agency $700,000.
panel and former president of Princeton University, delivered
the briefing. The group's study took 17 months and cost the stem cell
agency $700,000.
Hiltzik's piece summarized the IOM
proposals, which echoed many criticisms that have been aired for
years in California. Hiltzik wrote,
proposals, which echoed many criticisms that have been aired for
years in California. Hiltzik wrote,
"CIRM Chairman Jonathan
Thomas glided over those issues when he introduced Shapiro.
Thomas observed that the Institute of Medicine report included many
statements "validating CIRM, its process, what it was able to
achieve," which is a bit like launching the investigation of a
plane crash by focusing on all the planes that land safely every day.
Thomas did mention that the Institute of Medicine had made numerous
recommendation about how to "take something which is already a
great experience and improve it even further."
"Shapiro got only a few minutes
into his presentation before board members started interrupting him
with objections to the Institute of Medicine's recommendation for a
majority of independent members."
Hiltzik concluded,
"Thomas promised to stage a public
workshop on the Institute of Medicine report soon and to subject them
to 'lengthy discussion.'
"Does that sound as if the board
will be taking seriously the advice that it change the way it does
business? Stay tuned, but don't hold your breath."
Posted in Stem Cell Therapy, Stem Cells
Comments Off on LA Times: On the California Stem Cell Agency and Wasting $700,000
Appeals at the California Stem Cell Agency: Worthwhile or Worthless?
Jon Shestack, a patient advocate member
of the governing board of the California stem cell agency, weighed in
today on the virtues of the grant application appeal process at the
$3 billion research enterprise.
His remarks came in a “comment”
filed on the Duchenne item that appeared yesterday on this site. (His
full comment can be found at the end of that item.)
filed on the Duchenne item that appeared yesterday on this site. (His
full comment can be found at the end of that item.)
Shestack said that the handling of the
$6 million CIRM grant involving Duchenne research is “a casebook
study on why the special(extraordinary) petition is worthwhile. There
was indeed new and relevant information that only became available
after grant review. Scientific staff and leadership flagged it.”
$6 million CIRM grant involving Duchenne research is “a casebook
study on why the special(extraordinary) petition is worthwhile. There
was indeed new and relevant information that only became available
after grant review. Scientific staff and leadership flagged it.”
The utility of the petitions is one of
the reasons that we ran the story about Duchenne and the team at
UCLA. The extraordinary petition process is currently under fire by
both the Institute of Medicine and the stem cell agency itself, which
has appointed a task force to come up with changes. But, while the
petition process is certainly less than perfect, so is the peer
review/grant review process.
the reasons that we ran the story about Duchenne and the team at
UCLA. The extraordinary petition process is currently under fire by
both the Institute of Medicine and the stem cell agency itself, which
has appointed a task force to come up with changes. But, while the
petition process is certainly less than perfect, so is the peer
review/grant review process.
The Duchenne application is not the
only “case study.” An application by Karen Aboody of the City of
Hope is often cited as another case. There are undoubtedly others.
only “case study.” An application by Karen Aboody of the City of
Hope is often cited as another case. There are undoubtedly others.
The petition process was adopted
several years ago by the board as a tool to manage willy-nilly
appearances of scientists before the CIRM governing board whose
applications were rejected by reviewers. Now the Institute of
Medicine has recommended the petitions be abandoned, saying they
undermine the integrity of grant review process. The IOM cited a
major controversy in Texas involving its cancer research agency as an
example of how grant reviews or the lack of them can go bad – not
to mention conflict of interest problems there. CIRM has already
started to look for better solutions regarding appeals. Many of its directors
are troubled by emotional presentations from patients in
connection with petitions and the lack of adequate information to
make informed decisions on the spot about the contested matters.
several years ago by the board as a tool to manage willy-nilly
appearances of scientists before the CIRM governing board whose
applications were rejected by reviewers. Now the Institute of
Medicine has recommended the petitions be abandoned, saying they
undermine the integrity of grant review process. The IOM cited a
major controversy in Texas involving its cancer research agency as an
example of how grant reviews or the lack of them can go bad – not
to mention conflict of interest problems there. CIRM has already
started to look for better solutions regarding appeals. Many of its directors
are troubled by emotional presentations from patients in
connection with petitions and the lack of adequate information to
make informed decisions on the spot about the contested matters.
Whether appeals can be put in a tidy,
scientific box is debatable. Researchers have the right, under state
law, to address the board on any issue whatsoever. And at least some
of them will continue to do so -- regardless of any appeals changes -- when millions of dollars and their
careers are at stake.
scientific box is debatable. Researchers have the right, under state
law, to address the board on any issue whatsoever. And at least some
of them will continue to do so -- regardless of any appeals changes -- when millions of dollars and their
careers are at stake.
Opinions and decisions of CIRM
reviewers are not holy writ. They can and do make mistakes, as we
all do. In making changes in the appeals process, the goal of the
agency should be to devise a public and transparent process rather
than enshroud it in more secrecy. CIRM also should find a way to do
a much better job of communicating to applicants the availability of
appeals and precisely how to appeal when it becomes necessary.
reviewers are not holy writ. They can and do make mistakes, as we
all do. In making changes in the appeals process, the goal of the
agency should be to devise a public and transparent process rather
than enshroud it in more secrecy. CIRM also should find a way to do
a much better job of communicating to applicants the availability of
appeals and precisely how to appeal when it becomes necessary.
Posted in Stem Cell Therapy, Stem Cells
Comments Off on Appeals at the California Stem Cell Agency: Worthwhile or Worthless?
Winners From Today's Awards by the California Stem Cell Agency
The 12 winners in the latest round of grants from the California stem cell agency all come from institutions linked to directors on the agency's governing board. Board members with conflicts of interest are not allowed to vote on the grants or participate in the debate. Since the inception of the agency, more than 90 percent of its awards have gone to institutions linked to the directors. Here is a link to the CIRM press release on today's meeting.
Here is the list of researchers who won awards today.
New Faculty Physician Scientist Translational Research Awards
RN3-06530 | Robert Baloh | Cedars-Sinai Medical Center | $3,031,737.00 |
RN3-06378 | Reza Ardehali | University of California, Los Angeles | $2,930,388.00 |
RN3-06504 | Jason Pomerantz | University of California, San Francisco | $3,084,000.00 |
RN3-06396 | Mana Parast | University of California, San Diego | $3,013,252.00 |
RN3-06425 | Tracy Grikscheit | Children's Hospital of Los Angeles | $3,408,000.00 |
RN3-06532 | Tippi MacKenzie | University of California, San Francisco | $2,661,742.00 |
RN3-06479 | Ann Capela Zovein | University of California, San Francisco | $3,084,000.00 |
RN3-06529 | Alan Cheng | Stanford University | $3,091,595.00 |
RN3-06455 | Ali Nsair | University of California, Los Angeles | $3,004,315.00 |
RN3-06460 | Emanual Maverakis | University of California, Davis | $2,964,000.00 |
RN3-06510 | Michelle Monje | Stanford University | $2,800,536.00 |
RN3-06525 | Ophir Klein | University of California, San Francisco | $3,084,000.00 |
Total | $36,157,565.00 |
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/QdM4BZ5hPnc/winners-from-todays-awards-by.html
Posted in Stem Cell Therapy, Stem Cells
Comments Off on Winners From Today's Awards by the California Stem Cell Agency
Winners From Today’s Awards by the California Stem Cell Agency
The 12 winners in the latest round of grants from the California stem cell agency all come from institutions linked to directors on the agency's governing board. Board members with conflicts of interest are not allowed to vote on the grants or participate in the debate. Since the inception of the agency, more than 90 percent of its awards have gone to institutions linked to the directors. Here is a link to the CIRM press release on today's meeting.
Here is the list of researchers who won awards today.
New Faculty Physician Scientist Translational Research Awards
RN3-06530 | Robert Baloh | Cedars-Sinai Medical Center | $3,031,737.00 |
RN3-06378 | Reza Ardehali | University of California, Los Angeles | $2,930,388.00 |
RN3-06504 | Jason Pomerantz | University of California, San Francisco | $3,084,000.00 |
RN3-06396 | Mana Parast | University of California, San Diego | $3,013,252.00 |
RN3-06425 | Tracy Grikscheit | Children's Hospital of Los Angeles | $3,408,000.00 |
RN3-06532 | Tippi MacKenzie | University of California, San Francisco | $2,661,742.00 |
RN3-06479 | Ann Capela Zovein | University of California, San Francisco | $3,084,000.00 |
RN3-06529 | Alan Cheng | Stanford University | $3,091,595.00 |
RN3-06455 | Ali Nsair | University of California, Los Angeles | $3,004,315.00 |
RN3-06460 | Emanual Maverakis | University of California, Davis | $2,964,000.00 |
RN3-06510 | Michelle Monje | Stanford University | $2,800,536.00 |
RN3-06525 | Ophir Klein | University of California, San Francisco | $3,084,000.00 |
Total | $36,157,565.00 |
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/QdM4BZ5hPnc/winners-from-todays-awards-by.html
Posted in Stem Cell Therapy, Stem Cells
Comments Off on Winners From Today’s Awards by the California Stem Cell Agency
ViaCyte Wins Another $3 Million from California Stem Cell Agency
The California stem cell agency, which
has awarded ViaCyte, Inc., $36 million, today pumped another $3
million in the firm following the collapse of an alliance between the
San Diego firm and GlaxoSmithKline.
The now failed ViaCyte-Glaxo-CIRM
arrangement was ballyhooed by the CIRM in October because it would
have been the first deal involving Big Pharma and the stem cell
agency. The resources of Big Pharma are needed to pursue the
expensive path of turning stem cell research into cures.
arrangement was ballyhooed by the CIRM in October because it would
have been the first deal involving Big Pharma and the stem cell
agency. The resources of Big Pharma are needed to pursue the
expensive path of turning stem cell research into cures.
Meeting in Los Angeles, the CIRM
governing board approved the additional funds on a 13-0 vote with two abstentions. The action came following a closed door session to discuss how the funds would be spent. No details were provided publicly on that matter.
governing board approved the additional funds on a 13-0 vote with two abstentions. The action came following a closed door session to discuss how the funds would be spent. No details were provided publicly on that matter.
ViaCyte
has also told Biocentury that it is pursuing even more funding after
the alliance with Glaxo broke down. CIRM President Alan Trounson said ViaCyte is likely to receive another $3 million from the Juvenile Diabetes Research Foundation. Trounson also said that other sources are being examined as well.
Patricia Olson, executive director of
CIRM, scientific activities said the agency's advisors continue to have faith in ViaCyte's effort to develop a treatment for diabetes. The company plans to start a clinical trial on its product in
2014.
CIRM, scientific activities said the agency's advisors continue to have faith in ViaCyte's effort to develop a treatment for diabetes. The company plans to start a clinical trial on its product in
2014.
The ViaCyte-Glaxo-CIRM deal was cause for
celebration last fall. Alan Trounson, CIRM's president, said the
deal would “resound” globally. He told directors,
celebration last fall. Alan Trounson, CIRM's president, said the
deal would “resound” globally. He told directors,
“This is
verification of our program. To have (the head of Glaxo regenerative
medicine program) join us through a partnership arrangement with GSK
means that a project that we've shepherded from the basic science
through to the preclinical work and is heading to the clinic we're
now going to do in partnership with a very major organization.”
Posted in Stem Cell Therapy, Stem Cells
Comments Off on ViaCyte Wins Another $3 Million from California Stem Cell Agency